Call for Fierce 15 nominees

It's that time of year again.

The sixth annual Fierce 15, our take on a slate of the most promising private biotech companies in the world, will be coming out in June. And I'd like to know if you have any companies that you'd like me to consider.

It doesn't take much. Just a name e-mailed my way will suffice. I promise to take a look.

We've already identified a lengthy list of candidates this year, with some amazing managers, scientists and programs in the running. This is the most fun I have every year, and I'll be looking forward to seeing who you want to nominate. - John Carroll

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.